Life Forward Award
This award supports research aimed at advancing the quality of survivorship care by improving long-term support, follow-up, or well-being for patients beyond treatment.
The call for applications for the Life Forward Award 2027 is now OPEN!
Researchers working in hematology are invited to submit their project on behalf of their department and apply for the Life Forward Grant. All information on rules and regulations are available on the homepage, as is the application form.
The jury will select 1 or 2 innovative projects, which will be granted with a monetary prize of up to 20.000 EUR.
The award ceremony will take place at the 42nd BHS General Annual Meeting, March 12-13, 2027.
We are looking forward to receiving innovative projects that contribute the survivorship experience of individuals living beyond hematologic cancer treatment.
Sincerely,
Prof. Ann De Becker, President of the BHS
Submit your project
Participation requirements
The application must preferably be written in English** and must consist of :
- a detailed project form with a maximum of 3 pages including a budget estimate Detailed project form Life Forward Award 2027
- an information form containing the different project members and including the curriculum vitae of the applicant
- a summary in abstract format with a maximum of 2500 characters (including spaces) for possible publication in the Belgian Journal of Hematology
** applications in French or Dutch are acceptable, but the abstract/summary must be in English
Who can apply?
The candidate must fulfill all criteria below:
Young hematologists in training who are MD and are within 10 years after MD graduation
OR members of the multidisciplinary hospital team involved in hematology survivorship care, including (but not limited to):
- nurses
- nurse specialists
- physiotherapists
- psychologists
- dietitians
- social workers
- occupational therapists
- care coordinators
- other allied health professionals contributing to survivorship pathways
May not be an employee of the pharmaceutical industry
Which projects are eligible?
Innovative projects that focus on improving the survivorship experience of individuals living beyond hematologic cancer treatment. Eligible initiatives may address (but are not limited to):
- Long‑term physical, psychological, cognitive, or social effects of hematologic cancers or their treatments
- Models of care that improve follow‑up, rehabilitation, or reintegration into daily life
- Tools or programs that enhance quality of life, patient empowerment, or self‑management
- Research that advances understanding of survivorship challenges or outcomes
- Support initiatives for patients, families, or caregivers
- Innovative approaches using digital health, patient‑reported outcomes, or multidisciplinary care pathways
Projects should be carried out in the hospital or outpatient setting (with a clear link to a hospital environment). The project must not be directly linked to the use of a specific pharmaceutical specialty. All projects must comply with the Protection of Privacy Law.
This award has been made possible with an unrestricted grant from Daiichi Sankyo